219 views
Dr. Joaquín Martínez from the CRIS Unit of 12 de Octubre analyses the state of #lymphoma #research and its new developments in different treatments and diagnosis. The hematologist highlights the new drugs that help to combat this #cancer and the new methods of #diagnosis. Milagros is a patient of the CRIS Unit of 12 de Octubre and highlights the importance of #research to end this disease. Immunotherapy is key in the new blood cancer treatments that are being developed in the CRIS Hematological Tumors Unit to fight lymphoma. “One of our great advances is the development of a noninvasive and early diagnosis through liquid biopsy, which also provides us with more precise results,” says Dr. Joaquín Martínez. On World Lymphoma Day, CRIS against cancer claims the importance of investing in cancer research, since a long-lasting and stable commitment is necessary so that researchers can discover new treatments to stop a disease that continues to exist in times of pandemic. Proof of this is the HUNET-CRIS Hematological Tumor Unit at the 12 de Octubre University Hospital in Madrid, directed by Dr. Joaquín Martínez, head of the Hemato-Oncology Service at H12O, which has been funded by CRIS for 9 years. This unit has developed different lines of research into blood cancer, with more than 250 trials and treating more than 660 patients. Milagros, a lymphoma patient, remarks: “I have had this disease for two years, being treated at the CRIS Unit, and in these years I have seen how treatments have evolved. Therefore, I affirm the need to invest in research and thus be able to fight this disease.” Dr. Joaquín Martínez, “We must continue researching cancer, because it is here and it is evidently not going to be eliminated by Covid-19. The pandemic has created opportunities for us at the CRIS Unit, as it has allowed us to simplify procedures, optimize the work of some of the researchers, and have patients come to consultations less often without losing quality and efficiency.”